Previous Close | 4.6200 |
Open | 3.4000 |
Bid | 4.7000 |
Ask | 5.2500 |
Strike | 140.00 |
Expire Date | 2024-06-21 |
Day's Range | 3.1000 - 5.0000 |
Contract Range | N/A |
Volume | |
Open Interest | 3.85k |
Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024 — but the success comes with ongoing criticism about pricing and access.
These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.